Inve India ▾

Godrej Agrovet share price & results

Godrej Agrovet Limited· Fast Moving Consumer Goods

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Diversified Indian agri-business: animal feed, oil palm, crop protection, dairy & poultry/processed foods

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue2,205 ₹ crore+9.9% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin10.0 %−3.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit184 ₹ crore+8.9% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity21.21 %+3.2 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin10.23 %+2.2 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)8.56 %+10.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

4 of 9 judged targets kept · 16 open · verdicts reflect calls analysed to Q1 FY27.

Godrej Agrovet Limited management guidance track record on Inve: 25 targets tracked across analysed earnings calls (4 achieved, 5 missed, 16 open).

TargetOriginal wordingSaidLatest callVerdict
Astec LifeSciences CDMO Growth FY25Flat / No Growth
Call transcript, Q3 FY25 · 3 Feb 2025
Q3 FY25Q1 FY27:Historical promise for FY25, which was achieved. No further updates.
Call transcript, Q1 FY27 · 6 Aug 2026
Achieved
Consolidated Revenue Growth16% to 18%
Call transcript, Q4 FY25 · 5 May 2025
Q4 FY25Q1 FY27:Historical promise for FY26, which was officially missed. No further updates.
Call transcript, Q1 FY27 · 6 Aug 2026
Missed
Consolidated PBT Growth FY27Mid-strong double-digit, mid-teens
Call transcript, Q4 FY26 · 4 May 2026
Q4 FY26Q1 FY27:Guidance revised down from 'mid-strong double-digit, mid-teens' to just 'double-digit growth', with management to provide a specific range in Q2.
Call transcript, Q1 FY27 · 6 Aug 2026
Revised Down

Source: Inve Guidance Tracker for Godrej Agrovet Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

5 of Godrej Agrovet Limited's 25 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 22 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹584.5 −4.67% · −₹28.65

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −12.2% 1Y

₹500₹550₹600₹650Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 6 Nov 2025Q3 FY26 — 4 Feb 2026Q4 FY26 — 4 May 2026Q1 FY27 — 6 Aug 2026

1Y: ₹665.9 on 24 Oct 2025 → ₹584.5. High ₹676.05 (24 Sept 2026), low ₹513 (23 Jan 2026).

Previous close
₹613.15
Market cap
₹11.2k Cr
52-week range
₹513 – ₹676.05
One year
−12.51%
Price to earnings (TTM to Jun 2026)
24.00×
Return on equity (TTM to Jun 2026)
21.21%

Overview

Symbol
NSE:GODREJAGRO
Exchange
NSE
Currency
INR

What Godrej Agrovet Limited does

Based on the company's own presentations, annual report and earnings calls.

Godrej Agrovet is a diversified, R&D-oriented Indian agri-business operating across five verticals: animal nutrition (compound feed for cattle, poultry, fish and shrimp), oil palm (cultivation and processing into Crude Palm Oil and Palm Kernel Oil), crop protection/agrochemicals (via subsidiary Astec LifeSciences), dairy (via Creamline Dairy Products in Southern India) and poultry & processed foods (via wholly owned Godrej Foods Limited). It earns by manufacturing and selling compound feed to livestock and aqua farmers, processing palm fresh fruit bunches into edible oils, formulating and selling crop-care chemicals (including contract development and manufacturing for other companies), and processing and branding dairy and poultry/meat products for retail and institutional customers. It also holds a Bangladesh joint venture, ACI Godrej Agrovet, and is part of the Godrej Industries Group.

Segments

  • Animal Nutrition
  • Oil Palm
  • Crop Care
  • Dairy
  • Poultry & Processed Foods
  • Others
Manufacturing units (pan-India, across businesses)
60+
Animal feed manufacturing plants
30+
Market position — Animal Nutrition
Leading compound animal feed player in India across cattle, broiler, layer, fish and shrimp feed
Market position — Oil Palm
Largest producer of Crude Palm Oil (CPO) and Palm Kernel Oil (PKO) in India
R&D centres
Dedicated centres for Animal Nutrition (Nashik), Aqua Feed (Hanuman Junction, Andhra Pradesh), Chemical R&D (Rabale, Maharashtra — Astec LifeSciences) and an Oil Palm R&D farm (40 acres)
Group companies
Astec LifeSciences (listed agrochemicals subsidiary), Creamline Dairy Products, Godrej Foods Limited (wholly owned) and ACI Godrej Agrovet (Bangladesh joint venture)
Headquarters Mumbai, Maharashtra Company website

How the price took the results

close before → close after

Q1 FY27
−3.7%
6 Aug
Q4 FY26
−1.3%
4 May
Q3 FY26
+1.8%
4 Feb
Q2 FY26
−4.7%
6 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Godrej Agrovet Limited

Free account: one company. Everything above stays public.

Write why you follow Godrej Agrovet Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds